Biosimilar competition: Lessons from Europe

Nature Reviews Drug Discovery

Volumn 13, Issue 2, 2014, Pages 99-100

  Grabowski, Henry ^a   Guha, Rahul ^b   Salgado, Maria ^b  

^a DUKE UNIVERSITY   (United States)

^b International Arbitration and Litigation Practice   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOSIMILAR AGENT; ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR; INFLIXIMAB; MONOCLONAL ANTIBODY; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TUMOR NECROSIS FACTOR MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ANEMIA; COST CONTROL; DRUG APPROVAL; DRUG CONTROL; DRUG COST; DRUG MARKETING; ERYTHROPOIESIS; EUROPE; HUMAN; NEUTROPENIA; REIMBURSEMENT; SHORT SURVEY; UNITED STATES;

BIOSIMILAR PHARMACEUTICALS; DRUG APPROVAL; ECONOMIC COMPETITION; EUROPEAN UNION; LEGISLATION, DRUG; PRODUCT SURVEILLANCE, POSTMARKETING;

EID: 84895185576     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd4210     Document Type: Review

References (0)